Drug Abuse Aspects of HIV/AIDS (R21)

The summary for the Drug Abuse Aspects of HIV/AIDS (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Drug Abuse Aspects of HIV/AIDS (R21): Purpose. This Funding Opportunity Announcement (FOA) using the Exploratory/Developmental Grant (R21) encourages drug abuse research that addresses the changing dynamics of the HIV/AIDS epidemic in the U.S., such as the increasing over-representation of minorities and women among new AIDS cases and role of heterosexual sex as a transmission route. Studies are needed to develop novel preventive interventions that more effectively address the evolving epidemic. Internationally, studies are needed on how to translate and adapt interventions that have proved effective in the U.S. to other communities and international settings, and to learn from other conditions and cultures to inform our understanding of the causes, consequences, and differences in HIV-associated risks, morbidity, and mortality in diverse populations. The Exploratory/ Developmental Grant (R21) is intended for early and conceptual research development, for example to assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Such studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of innovative techniques, agents, methodologies, models or applications that could have major impact on a field of biomedical, behavioral, or clinical research. Applications for R21 awards should be for projects distinct from those supported through the traditional R01 mechanism. Long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications submitted under the R21 mechanism should be exploratory and novel, and seek to break new ground or extend previous discoveries toward new directions or applications.
Federal Grant Title: Drug Abuse Aspects of HIV/AIDS (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-07-309
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: No deadline provided
Original Application Deadline: Multiple Receipt Dates - See Link to Full Announce
Posted Date: Jan 17, 2007
Creation Date: Jan 17, 2007
Archive Date: Dec 05, 2008
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments For profit organizations other than small businesses Public and State controlled institutions of higher education Private institutions of higher education Native American tribal governments (Federally recognized) County governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Others (see text field entitled "Additional Information on Eligibility" for clarification) State governments
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
Clinical Sites for the ECHO IDeA States Pediatric Clinical Trials Network - 2 (UG1 Clinica...
Data Coordinating and Operations Center for the ECHO IDeA States Pediatric Clinical Trials...
NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Tri...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Limited Competition: AIDS Malignancy Consortium (AMC) (UM1 Clinical Trials Required)
Advancing Sustained/Extended Release for HIV Prevention (A-SER) (R01 Clinical Trial Not Al...
Resource-Related Research Projects for Development of Animal Models and Related Materials ...
Tailoring Interventions to Improve Preventive Health Service Use (R61/R33 Clinical Trial R...
Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinica...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com